Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 3
1970 1
1971 3
1972 1
1974 2
1975 4
1976 6
1977 2
1978 7
1980 7
1981 7
1982 3
1983 6
1984 3
1985 4
1986 6
1987 3
1988 4
1989 3
1990 3
1991 2
1992 1
1993 2
1994 4
1995 4
1996 1
1997 4
1998 1
2000 3
2001 2
2003 1
2004 3
2006 1
2007 2
2008 2
2010 2
2011 1
2012 1
2013 1
2014 1
2017 2
2018 3
2019 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

121 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean g modes (9,327 results)?
Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.
Lichner Z, Saleeb R, Butz H, Ding Q, Nofech-Mozes R, Riad S, Farag M, Varkouhi AK, Dos Santos CC, Kapus A, Yousef GM. Lichner Z, et al. FASEB J. 2019 Jan;33(1):1347-1359. doi: 10.1096/fj.201800596R. Epub 2018 Aug 27. FASEB J. 2019. PMID: 30148679
In summary, we suggest that sunitinib-resistant RCC cells exist in treatment-sensitive tumors and are histologically identifiable.-Lichner, Z., Saleeb, R., Butz, H., Ding, Q., Nofech-Mozes, R., Riad, S., Farag, M., Varkouhi, A. K., dos Santos, C. C., Kapus, A., Yousef, …
In summary, we suggest that sunitinib-resistant RCC cells exist in treatment-sensitive tumors and are histologically identifiable.-Lichner, …
Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases.
Tankersley DL. Tankersley DL. Immunol Rev. 1994 Jun;139:159-72. doi: 10.1111/j.1600-065x.1994.tb00861.x. Immunol Rev. 1994. PMID: 7927410 Review.
Experimental animal models of autoimmune disease, such as the mouse model for systemic lupus erythematosus (Mozes et al. 1993), might be very useful in this regard. Finally, it needs to be emphasized that the usefulness of high doses of Igi.v. in many autoimmune diseases r …
Experimental animal models of autoimmune disease, such as the mouse model for systemic lupus erythematosus (Mozes et al. 1993), might …
Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
Sthoeger Z, Sharabi A, Mozes E. Sthoeger Z, et al. J Autoimmun. 2014 Nov;54:60-71. doi: 10.1016/j.jaut.2014.06.002. Epub 2014 Jun 21. J Autoimmun. 2014. PMID: 24958634 Review.
In addition to the non-antigen specific agents that may affect the normal immune system as well, SLE-specific therapeutic means are under development. These are synthetic peptides (e.g. pConsensus, nucleosomal peptides, P140 and hCDR1) that are sequences of conserved regio …
In addition to the non-antigen specific agents that may affect the normal immune system as well, SLE-specific therapeutic means are under de …
The genetic control of antibody specificity.
Mozes E, McDevitt HO, Jaton JC, Sela M. Mozes E, et al. J Exp Med. 1969 Dec 1;130(6):1263-78. doi: 10.1084/jem.130.6.1263. J Exp Med. 1969. PMID: 4187525 Free PMC article.
F(1) x DBA/1 backcross anti-(Phe, G)-Pro--L sera segregate in their ability to bind (T,G)-Pro--L, and there is no linkage of anti-(T,G)-Pro--L binding capacity with the H-2(s) allele of the SJL grandparent. F(1) x SJL anti-(Phe, G)-Pro-L sera segregate …
F(1) x DBA/1 backcross anti-(Phe, G)-Pro--L sera segregate in their ability to bind (T,G)-Pro--L, and there is no linkage of a …
A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
Mozes E, Sharabi A. Mozes E, et al. Autoimmun Rev. 2010 Nov;10(1):22-6. doi: 10.1016/j.autrev.2010.07.004. Epub 2010 Jul 23. Autoimmun Rev. 2010. PMID: 20659591 Review.
The beneficial effects were associated with a diminished production of pathogenic cytokines (e.g. IFN-gamma, IL-10, and IL-1beta) and with increased production of the immunosuppressive cytokine, TGF-beta. ...
The beneficial effects were associated with a diminished production of pathogenic cytokines (e.g. IFN-gamma, IL-10, and IL-1beta) and …
The nature of the antigenic determinant in a genetic control of the antibody response.
Mozes E, McDevitt HO, Jaton JC, Sela M. Mozes E, et al. J Exp Med. 1969 Sep 1;130(3):493-504. doi: 10.1084/jem.130.3.493. J Exp Med. 1969. PMID: 5807278 Free PMC article.
This was confirmed by studying the response of different mouse strains to two kinds of polypeptides: (T,G)-Pro-A--L 717 and 718 and (T,G)-A-Pro--L 719 and 721. Antibody assay of antisera to (Phe,G)-Pro--L with the cross-reacting antigens (T,G)-Pro--L a …
This was confirmed by studying the response of different mouse strains to two kinds of polypeptides: (T,G)-Pro-A--L 717 and 718 and ( …
Specificity of genes controlling immune responsiveness to (T,G)-A--L and (Phe,G)-A--L.
Lifshitz R, Schwartz M, Mozes E. Lifshitz R, et al. Immunology. 1980 Oct;41(2):339-46. Immunology. 1980. PMID: 6777289 Free PMC article.
Mice possessing the H-2b haplotype are high responders to the cross-reactive antigens (T,G)-A--L and (Phe,G)-A--L whereas mice with the H-2k haplotype respond only to (Phe,G)-A--L. ...Only (Phe,G)-A--L primed and boosted H-2k mice produced high levels …
Mice possessing the H-2b haplotype are high responders to the cross-reactive antigens (T,G)-A--L and (Phe,G)-A--L whereas mice …
Oil-Based or Water-Based Contrast for Hysterosalpingography in Infertile Women.
Dreyer K, van Rijswijk J, Mijatovic V, Goddijn M, Verhoeve HR, van Rooij IAJ, Hoek A, Bourdrez P, Nap AW, Rijnsaardt-Lukassen HGM, Timmerman CCM, Kaplan M, Hooker AB, Gijsen AP, van Golde R, van Heteren CF, Sluijmer AV, de Bruin JP, Smeenk JMJ, de Boer JAM, Scheenjes E, Duijn AEJ, Mozes A, Pelinck MJ, Traas MAF, van Hooff MHA, van Unnik GA, de Koning CH, van Geloven N, Twisk JWR, Hompes PGA, Mol BWJ. Dreyer K, et al. N Engl J Med. 2017 May 25;376(21):2043-2052. doi: 10.1056/NEJMoa1612337. Epub 2017 May 18. N Engl J Med. 2017. PMID: 28520519 Free article. Clinical Trial.
Dichotomy between the T and the B cell epitopes of the synthetic polypeptide (T,G)-A--L.
Zisman E, Sela M, Ben-Nun A, Mozes E. Zisman E, et al. Eur J Immunol. 1994 Oct;24(10):2497-505. doi: 10.1002/eji.1830241036. Eur J Immunol. 1994. PMID: 7523144
Thus, we were interested to elucidate the major T cell epitope of (T,G)-A--L, by using the ordered polypeptides (T-T-G-G)-A--L and (T-G-T-G)-A--L, in which only the two internal amino acids of the tetrapeptide attached to the side chains are swi …
Thus, we were interested to elucidate the major T cell epitope of (T,G)-A--L, by using the ordered polypeptides (T-T-G-G
Pathogenic idiotypes of autoantibodies in autoimmunity: lessons from new experimental models of SLE.
Shoenfeld Y, Mozes E. Shoenfeld Y, et al. FASEB J. 1990 Jun;4(9):2646-51. doi: 10.1096/fasebj.4.9.2140806. FASEB J. 1990. PMID: 2140806 Review.
The disease is characterized clinically (proteinuria), serologically (e.g., anti-dsDNA, anti-Sm antibodies), and by pathological findings (e.g., deposition of 16/6 Id in the kidneys). ...
The disease is characterized clinically (proteinuria), serologically (e.g., anti-dsDNA, anti-Sm antibodies), and by pathological find …
121 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page